# Valence Advantage Life Sciences Fund II, L.P. — Form D/A

Valence Advantage Life Sciences Fund II, L.P. of NEW YORK, NY, a pooled investment fund, filed a Form D amendment with the SEC on 2013-03-14. The offering totals $175.0M, of which $60.8M was reported sold. Industry: Pooled Investment Fund.

## Offering

- Filed: 2013-03-14
- Form: D/A
- Accession: 0001544406-13-000001
- Industry: Pooled Investment Fund
- Exemptions: 06, 3C, 3C.7
- Total offering: $175.0M
- Amount sold: $60.8M
- Remaining: $114.2M
- Investors: 11
- Date of first sale: 2012-03-30
- Security types: fund interests
- Revenue range: Decline to Disclose
- SEC file number: 021-174950

## Issuer

- Name: Valence Advantage Life Sciences Fund II, L.P.
- CIK: 0001544406
- Entity type: Limited Partnership
- Jurisdiction: DELAWARE
- Incorporated: 2012
- Address: 500 PARK AVENUE, 9TH FLOOR, NEW YORK, NY, 10022
- Phone: 212-891-1100

## Officers, directors & promoters (5)

| Name | Role | Location |
| --- | --- | --- |
| Jay Rachel Cecil | Director | New York, NY |
| A. Rachel Leheny | Director | La Jolla, CA |
| Scott Rachel Morenstein | Director | New York, NY |
| Eric W Roberts | Director | La Jolla, CA |
| N/A Valence Life Sciences GP II, LLC | Promoter | New York, NY |

## Other filings by this issuer (1)

| Filed | Form | Offering | Sold |
| --- | --- | --- | --- |
| [2012-03-14](https://search.stillhousedata.com/formd/0001544406-12-000001) | D | $175.0M | — |

## More

- [CIK 1544406 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1544406&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001544406-13-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.